What is the brand name of letrozole, the first‑line agent for ovulation induction in women with polycystic ovary syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Femara

Letrozole is marketed under the brand name Femara 1.

Letrozole is a nonsteroidal aromatase inhibitor that has become the first-line pharmacological agent for ovulation induction in women with polycystic ovary syndrome (PCOS), representing a significant shift from older guidelines that recommended clomiphene citrate 2. This change reflects superior evidence for pregnancy and live birth outcomes with letrozole compared to clomiphene citrate.

Key Clinical Context

The drug is FDA-approved primarily for breast cancer treatment in postmenopausal women, but its use in ovulation induction has become standard practice based on robust clinical evidence. Three major clinical practice guidelines from 2021 now recommend letrozole as the primary method of pharmacological ovulation induction in PCOS 2.

Evidence Supporting First-Line Use

Recent meta-analyses demonstrate letrozole's superiority over clomiphene citrate:

  • Higher ovulation rates (18% increase)
  • Higher pregnancy rates (57% increase)
  • Higher live birth rates (54% increase)
  • Lower multiple pregnancy risk (58% reduction) 3

Treatment Algorithm

For women with PCOS seeking pregnancy:

  1. First-line: Lifestyle modifications for 3-6 months 2
  2. Second-line: Letrozole for pharmacological ovulation induction 2, 4
  3. Third-line: Gonadotropins or laparoscopic ovarian drilling 2
  4. Fourth-line: In vitro fertilization 2, 4

Important caveat: Some guidelines consider pharmacological ovulation induction contraindicated in obese women with BMI >35 kg/m² until weight optimization 2.

References

Related Questions

What is the appropriate letrozole dosing regimen for ovulation induction in patients with polycystic ovary syndrome (PCOS)?
How does letrozole induce ovulation and improve fertility in women with polycystic ovary syndrome (PCOS)?
What are the effects of administering letrozole without a preceding menstrual period in an anovulatory PCOS patient?
Can letrozole 2.5 mg cause diabetes?
During a phone triage, what questions should I ask a female patient who reports dizziness associated with letrozole use?
What is the recommended management for a child with primary vesicoureteric reflux grade 4?
In a patient with chronic obstructive pulmonary disease and left-sided heart failure, should trimetazidine be used as therapy?
What should a brittle type 1 diabetic do during the day to maintain steady blood glucose while using an insulin pump?
Can a nasopharyngeal tumor cause hearing loss?
What is the appropriate dosing regimen of oral immediate‑release nifedipine 20 mg for acute management of postpartum hypertension?
In an 18‑year‑old patient with negative hepatitis B surface antibody (anti‑HBs) despite prior hepatitis B vaccination, what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.